This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hachulla, E Articles by Devulder, B Search for Related Content PubMed PubMed Citation Articles by Hachulla, E Articles by Devulder, B Social Bookmarking                         What's this?

Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies

U Michon-Pasturel

Department of Internal Medicine; University of Lille, France

D Leys

Department of Neurology; University of Lille, France

J-P Pruvo

Department of Neuroradiology; University of Lille, France

V Queyrel

Department of Internal Medicine; University of Lille, France

E Masy

Department of Immunological Laboratory; University of Lille, France

J Arvieux

Immunological Laboratory, CTS Grenoble, France

C Caron

Department of Hemostasis Laboratory, University of Lille, France

F Brevet-Coupeé

P-Y Hatron

B Devulder

Department of Internal Medicine; University of Lille, France

Objective: To determine in patients with systemic lupus erythematosus (SLE) or with primary antiphospholipid syndrome (PAPS) the prevalence of cerebral magnetic resonance imaging changes (MRI) and the relationship with antiphospholipid antibodies.

Methods: Twenty-nine consecutive SLE patients, 24 PAPS patients and 31 healthy controls were prospectively included in the study and underwent MRI Scan over a 1-year period. MRI scans were analyzed separately by a neuroradiologist for white matter changes [periventricular hyperintensity (PVH) (0–6 scale), deep white matter hyperintensity (WMH) (0–24 scale)], and one neurologist for cerebral atrophy (0–39 scale) and stroke subtypes. Statistical assessment consisted of a discriminant analysis performed with SAS-package with MRI data as dependent variables and, as independent variables, age, sex, arterial hypertension, diabetes mellitus, cardiopathy, migraine, neurological symptoms, antiphospholipid antibodies, SLE, steroid treatment.

Results: The prevalence of cerebral atrophy was increased in both SLE and PAPS groups relative to controls. PVH and WMH scores were significantly higher in SLE and PAPS than in controls. Focal infarct did not differ in the SLE group when compared with PAPS. PVH and WMH scores were significantly higher in patients with neurological symptoms. Using a correlation test we found a weak significant correlation between cerebral atrophy and lupus anticoagulant. The multivariate analysis found only three independent variables related to PVH and WMH: age, the diagnosis of SLE and cerebral atrophy.

Conclusions: Age, presence of SLE and presence of neurological symptoms were independently related with WMH and PVH, but not antiphospholipid antibodies.

Key Words: Lupus erythematosus • primary antiphospholipid syndrome • magnetic resonance imaging

Lupus, Vol. 7, No. 2, 124-131 (1998)
DOI: 10.1191/096120398678919868


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Kimura, T. Sakurai, Y. Tanaka, I. Hozumi, K. Takahashi, M. Takemura, K. Saito, M. Seishima, and T. Inuzuka Proteomic analysis of autoantibodies in neuropsychiatric systemic lupus erythematosus patient with white matter hyperintensities on brain MRI Lupus, January 1, 2008; 17(1): 16 - 20. [Abstract] [PDF]

				M. G. Tektonidou, N. Varsou, G. Kotoulas, A. Antoniou, and H. M. Moutsopoulos Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med, November 13, 2006; 166(20): 2278 - 2284. [Abstract] [Full Text] [PDF]

				J Serelis, M G Tektonidou, and F N Skopouli A case with epilepsy, cognitive impairment, renal microangiopathy and high titres of anticentromere and anticardiolipin antibodies Lupus, August 1, 2005; 14(8): 625 - 628. [Abstract] [PDF]

				S. Ferreira, D. P. D'Cruz, and G. R. V. Hughes Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology, April 1, 2005; 44(4): 434 - 442. [Abstract] [Full Text] [PDF]

				G. J. del Zoppo TIAs and the pathology of cerebral ischemia Neurology, April 27, 2004; 62(8_suppl_6): S15 - S19. [Full Text]

				S D Denburg and J A Denburg Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus Lupus, December 1, 2003; 12(12): 883 - 890. [Abstract] [PDF]

				G. Ruiz-Irastorza and M.A. Khamashta Warfarin for multiple sclerosis? QJM, August 1, 2000; 93(8): 497 - 499. [Full Text] [PDF]

				M Rovaris, B Viti, G Ciboddo, S Gerevini, R Capra, G Iannucci, G Comi, and M Filippi Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study J. Neurol. Neurosurg. Psychiatry, February 1, 2000; 68(2): 170 - 177. [Abstract] [Full Text] [PDF]

				R. Brey and A. Escalante Review : Neurological manifestations of antiphospholipid antibody syndrome Lupus, January 1, 1998; 7(2_suppl): S67 - S74. [Abstract] [PDF]

				J-C. Piette Review : Towards improved criteria for the antiphospholipid syndrome Lupus, January 1, 1998; 7(2_suppl): S149 - S157. [Abstract] [PDF]